Predicting Cardiovascular Risk in Participants Treated With Tirzepatide in the SURPASS 1-5 Trials

被引：0
|
作者：
Wiese, Russell J.
Wang, Hui
Mody, Reema
Benneyworth, Brian D.
机构：
来源：
CIRCULATION | 2023年 / 148卷
关键词：
Diabetes (Type II); Cardiovascular Risk; Drugs; Prediction model; Clinical trials;
D O I：
10.1161/circ.148.suppl_1.16589
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A16589
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Tirzepatide as a Novel Therapeutic Option for Patients with Type 2 Diabetes: A Pooled Analysis of Subgroups of SURPASS 1-5 Trials
    Abdalla, Mohammed Altigani
    Soyiri, Ireneous
    Atkin, Stephen
    Sathyapalan, Thozhukat
    JOURNAL OF DIABETOLOGY, 2023, 14 (02) : 65 - 73
  • [2] Duration of Sustained Weight Loss in Clinical Trials Evaluating Tirzepatide vs. Comparators-An Exploratory Analysis of SURPASS 1-5
    Garvey, W. Timothy
    Batterham, Rachel L.
    Rosenstock, Julio
    Liu, Minzhi
    Thieu, Vivian
    Daly, Jack
    Bergman, Brandon
    DIABETES, 2023, 72
  • [3] Time spent in glucose control after initiating tirzepatide vs comparators: exploratory analysis of fasting serum glucose in SURPASS 1-5 trials
    Batterham, R. L.
    Rosenstock, J.
    Garvey, W. T.
    Liu, M.
    Chen, Y.
    Bergman, B. K.
    Hemmingway, A.
    Thieu, V. T.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S341 - S342
  • [4] Longer Time Spent in Glycemic Control after Initiating Tirzepatide vs. Comparators-Exploratory Analysis of SURPASS 1-5 Trials
    Rosenstock, Julio
    Garvey, W. Timothy
    Batterham, Rachel L.
    Liu, Minzhi
    Bergman, Brandon
    Hemmingway, Andrea
    Thieu, Vivian
    DIABETES, 2023, 72
  • [5] Tirzepatide leads to significant improvement in postprandial glycaemic control in people with type 2 diabetes (SURPASS 1-5)
    Lee, C. J.
    Spanakis, E.
    Bray, R.
    Brown, K.
    Billings, L. K.
    Chivukula, K.
    Rodriguez, A.
    Giorgino, F.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S300 - S301
  • [6] Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials
    Rosenstock, Julio
    Vazquez, Luis
    Del Prato, Stefano
    Franco, Denise Reis
    Weerakkody, Govinda
    Dai, Biyue
    Lando, Laura Fernandez
    Bergman, Brandon K.
    Rodriguez, Angel
    DIABETES CARE, 2023, 46 (11) : 1986 - 1992
  • [7] Tirzepatide reduces albuminuria in patients with type 2 diabetes: post-hoc pooled analysis of SURPASS 1-5
    Wiese, R. J.
    Heerspink, H. J. L.
    Tuttle, K. R.
    Pavo, I.
    Haupt, A.
    Yang, Z.
    Hemmingway, A.
    Cherney, D. Z. I.
    Sattar, N.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S4 - S4
  • [8] Tirzepatide Reduces Albuminuria in Patients with T2D-Post Hoc Pooled Analysis of SURPASS 1-5
    Heerspink, Hiddo L.
    Tuttle, Katherine R.
    Pavo, Imre
    Haupt, Axel
    Yang, Zhengyu
    Wiese, Russell
    Hemmingway, Andrea
    Cherney, David
    Sattar, Naveed
    DIABETES, 2023, 72
  • [9] Characterization of Tirzepatide-Treated patients achieving HbA1c <5.7% in the SURPASS 1-4 Trials
    Rosenstock, Julio
    Del Prato, Stefano
    Franco, Denise R.
    Vazquez, Luis A.
    Dai, Biyue
    Weerakkody, Govinda J.
    Lando, Laura Fernandez
    Rodriguez, Angel
    Bergman, Brandon
    DIABETES, 2022, 71
  • [10] Characterization of tirzepatide-treated patients achieving HbA1c <5.7% in the SURPASS 1-4 trials
    Rosenstock, Julio
    Del Prato, Stefano
    Franco, Denise Reis
    Vazquez, Luis
    Dai, Biyue
    Weerakkody, Govinda
    Fernandez-Lando, Laura
    Rodriguez, Angel
    Bergman, Brandon K.
    Chen, Xi
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 153
12345